A method to estimate treatment efficacy among latent subgroups of a randomized clinical trial

被引:26
作者
Altstein, Lily L. [1 ]
Li, Gang [1 ]
Elashoff, Robert M. [1 ,2 ]
机构
[1] Univ Calif Los Angeles, Dept Biostat, Sch Publ Hlth, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Med Ctr, Dept Biomath, Los Angeles, CA 90095 USA
关键词
survival analysis; accelerated failure time model; treatment noncompliance; mixture model; EM algorithm; FACTOR INTERVENTION TRIAL; SENTINEL-NODE BIOPSY; EARLY-STAGE MELANOMA; TREATMENT-NONCOMPLIANCE; INSTRUMENTAL VARIABLES; MULTICENTER TRIAL; MODELS; LIKELIHOOD; INFERENCE; COMPLIERS;
D O I
10.1002/sim.4131
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Subgroup analysis arises in clinical trials research when we wish to estimate a treatment effect on a specific subgroup of the population distinguished by baseline characteristics. Many trial designs induce latent subgroups such that subgroup membership is observable in one arm of the trial and unidentified in the other. This occurs, for example, in oncology trials when a biopsy or dissection is performed only on subjects randomized to active treatment. We discuss a general framework to estimate a biological treatment effect on the latent subgroup of interest when the survival outcome is right-censored and can be appropriately modelled as a parametric function of covariate effects. Our framework builds on the application of instrumental variables methods to all-or-none treatment noncompliance. We derive a computational method to estimate model parameters via the EM algorithm and provide guidance on its implementation in standard software packages. The research is illustrated through an analysis of a seminal melanoma trial that proposed a new standard of care for the disease and involved a biopsy that is available only on patients in the treatment arm. Copyright (C) 2010 John Wiley & Sons, Ltd.
引用
收藏
页码:709 / 717
页数:9
相关论文
共 26 条
[1]   Bootstrap tests for distributional treatment effects in instrumental variable models [J].
Abadie, A .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 2002, 97 (457) :284-292
[2]  
Angrist JD, 1996, J AM STAT ASSOC, V91, P444, DOI 10.2307/2291629
[3]  
Cantor A., 2003, SAS survival analysis techniques for medical research
[4]   Estimating the effect of treatment in a proportional hazards model in the presence of non-compliance and contamination [J].
Cuzick, Jack ;
Sasieni, Peter ;
Myles, Jonathan ;
Tyrer, Jonathan .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 2007, 69 :565-588
[5]   MAXIMUM LIKELIHOOD FROM INCOMPLETE DATA VIA EM ALGORITHM [J].
DEMPSTER, AP ;
LAIRD, NM ;
RUBIN, DB .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-METHODOLOGICAL, 1977, 39 (01) :1-38
[6]   Estimating treatment effects from randomized clinical trials with noncompliance and loss to follow-up: the role of instrumental variable methods [J].
Dunn, G ;
Maracy, M ;
Tomenson, B .
STATISTICAL METHODS IN MEDICAL RESEARCH, 2005, 14 (04) :369-395
[7]   On the effect of treatment among would-be treatment compliers: An analysis of the Multiple Risk Factor Intervention Trial [J].
Follmann, DA .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 2000, 95 (452) :1101-1109
[8]   Addressing complications of intention-to-treat analysis in the combined presence of all-or-none treatment-noncompliance and subsequent missing outcomes [J].
Frangakis, CE ;
Rubin, DB .
BIOMETRIKA, 1999, 86 (02) :365-379
[9]   Principal stratification in causal inference [J].
Frangakis, CE ;
Rubin, DB .
BIOMETRICS, 2002, 58 (01) :21-29
[10]  
Imbens GW, 1997, ANN STAT, V25, P305